Key facts
- This page summarizes Benjamin Zimmer's Form 3 filing for Roivant Sciences Ltd. (ROIV).
- 0 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 01 Oct 2021, 17:41.
Benjamin Zimmer - 01 Oct 2021 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- President, Roivant Health
- Issuer ticker
- ROIV
- Reported as of
- 01 Oct 2021
- Net transaction value
- $0
- Reporting owner signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Benjamin Zimmer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Benjamin Zimmer filed Form 3 for Roivant Sciences Ltd. (ROIV) on 01 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,167,491
- Date
- 01 Oct 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 1,185
- Exercise price
- $5.12
- Footnotes
- F2
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 4,424
- Exercise price
- $3.97
- Footnotes
- F2
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 1,463,100
- Exercise price
- $10.96
- Footnotes
- F3, F8
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 181,828
- Exercise price
- $12.68
- Footnotes
- F4, F8
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 422,967
- Exercise price
- $13.78
- Footnotes
- F5, F8
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 614,502
- Exercise price
- $13.07
- Footnotes
- F6, F8
ROIV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 731,549
- Exercise price
- $10.00
- Footnotes
- F7, F8
ROIV
holding
Derivative
Capped Value Appreciation Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 181,828
- Exercise price
- $11.50
- Footnotes
- F9, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
Includes (i) an award of 731,550 restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of May 20, 2019, (ii) an award of 266,017 RSUs with a vesting commencement date of May 20, 2021 and (iii) an award of 169,924 shares of restricted stock covering Common Shares ("RSAs"). The awards of RSUs service-vest (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. The award of RSAs is fully vested.
Footnote F2
Award of stock options to purchase Common Shares that is fully vested.
Footnote F3
Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2019.
Footnote F4
Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019.
Footnote F5
Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019.
Footnote F6
Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2020.
Footnote F7
Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2021.
Footnote F8
Awards of stock options to purchase Common Shares vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.
Footnote F9
Reflects an award of capped value appreciation rights ("CVARs") that entitle the reporting person to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 4 of Table II above (such excess, the "CVAR Amount"). The CVARs will be settled in a number of Common Shares determined by dividing (i) the applicable CVAR Amount by (ii) the fair market value of a Common Share as of the applicable payment date.
Footnote F10
These awards of CVARs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019.
SEC remarks
Exhibit 24 - Power of Attorney